Elutia Past Earnings Performance
Past criteria checks 0/6
Elutia's earnings have been declining at an average annual rate of -27.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 30.1% per year.
Key information
-27.8%
Earnings growth rate
56.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -30.1% |
| Return on equity | n/a |
| Net Margin | -280.5% |
| Next Earnings Update | 14 Nov 2024 |
Recent past performance updates
Recent updates
Elutia Inc.'s (NASDAQ:ELUT) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Jun 28
News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat
Mar 10Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues
Feb 21Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding
Apr 17Aziyo Biologics appoints Williams as Chief Scientific Officer
Aug 26Aziyo Biologics names co-founder C. Randal Mills as permanent CEO
Aug 10Revenue & Expenses Breakdown
How Elutia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 25 | -70 | 28 | 4 |
| 31 Mar 24 | 25 | -49 | 27 | 4 |
| 31 Dec 23 | 25 | -41 | 27 | 4 |
| 30 Sep 23 | 25 | -32 | 28 | 5 |
| 30 Jun 23 | 25 | -35 | 31 | 6 |
| 31 Mar 23 | 19 | -38 | 33 | 7 |
| 31 Dec 22 | 24 | -36 | 34 | 8 |
| 30 Sep 22 | 28 | -39 | 34 | 9 |
| 30 Jun 22 | 34 | -37 | 34 | 10 |
| 31 Mar 22 | 46 | -28 | 33 | 10 |
| 31 Dec 21 | 47 | -25 | 33 | 9 |
| 30 Sep 21 | 49 | -21 | 33 | 8 |
| 30 Jun 21 | 49 | -23 | 32 | 7 |
| 31 Mar 21 | 46 | -26 | 29 | 6 |
| 31 Dec 20 | 43 | -25 | 28 | 6 |
| 30 Sep 20 | 42 | -23 | 28 | 5 |
| 30 Jun 20 | 42 | -16 | 28 | 4 |
| 31 Mar 20 | 43 | -13 | 27 | 3 |
| 31 Dec 19 | 43 | -12 | 26 | 2 |
| 31 Dec 18 | 39 | -12 | 22 | 2 |
Quality Earnings: ELUT is currently unprofitable.
Growing Profit Margin: ELUT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ELUT is unprofitable, and losses have increased over the past 5 years at a rate of 27.8% per year.
Accelerating Growth: Unable to compare ELUT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ELUT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: ELUT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.